Live
- Concerns Over NASA Astronaut Sunita Williams' Health After Recent Photos Show Significant Weight Loss
- Chandrababu holds meeting with ministers, discusses on SC Classification
- National anti-terror policy, strategy to be unveiled soon: HM Shah
- Donald Trump Effect: Gold Prices Drop Sharply in a Single Day
- Australian govt to ban social media access for children younger than 16
- ED conducts raids on multiple sellers linked to e-com players including Amazon, Flipkart
- India A vs Australia A: Contrasting outings for KL Rahul and Dhruv Jurel at Melbourne
- Lakshya and Ananya Panday Pair Up in Dharma Productions' Next Big Film
- After political furore, BJP leader withdraws slur on Sharad Pawar
- Kerala Cong cries foul over police raid on hotel rooms of women leaders, moves ECI
After More Than A Decade: Chinese regulator gives nod for Dr Reddy's cardiac drug
After a 11-year long wait, Dr Reddy’s Laboratories (Dr Reddy’s) has finally bagged the approval from the Chinese regulator for its anti-blood clotting drug Clopidogrel.
Hyderabad: After a 11-year long wait, Dr Reddy's Laboratories (Dr Reddy's) has finally bagged the approval from the Chinese regulator for its anti-blood clotting drug Clopidogrel.
The Chinese regulator has shown a green flag to the drug, which is expected to land up in sales worth over Rs 11,175 crore ($1.6 billion).
The drug is indicative of preventing blood clotting primarily and acts against cardiovascular issues.
Clopidogrel, sold under the trade name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk.
According to a clarification given to stock exchanges, the city-based drug maker said sales of this drug would not be materialised in the current financial year.
"Please note that the Company has received approval for the product Clopidogrel in China.The Company believes that the sales from this product will not be material in the current financial year i.e. FY2020," Dr Reddy's said.
Prior to this in 2012, DRL had launched generic Clopidogrel in the United States market along with its partner Mylan. The move came in following the expiry of patent for Sanofi-Aventis' Plavix, one of the best-selling drugs in the US.
During the patent period, the drug approximately had an annual sale of around $6.7 billion. According to Edelweiss analyst, DRL has seven to eight products lined up for approval from the Chinese drug regulator and it expects to increase the number of filings.
"DRL is the largest international generic pharmaceutical company in China with presence across all provinces.
In FY18, DRL clocked around $100 million sales from 8-10 products with sales accounted for in its joint venture (JV), Kunshan Rotam Reddy (DRL owns 51.3 per cent interest)," Edelweiss said.
